Skip to search formSkip to main content
You are currently offline. Some features of the site may not work correctly.

Symbicort Turbuhaler

National Institutes of Health

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2018
2018
BackgroundThe utility and effectiveness of inhalational asthma therapy in patients with a permanent tracheostomy has not been… Expand
  • figure 1
2012
2012
BackgroundTherapeutic reference pricing (TRP) based on the WHO daily defined dose (DDD) is a method frequently employed for the… Expand
  • table 1
  • table 2
  • table 3
  • table 4
Review
2012
Review
2012
Chronic obstructive pulmonary disease (COPD) is a highly heterogeneous, progressive inflammatory disease that imposes… Expand
  • table I
  • table II
  • figure 1
  • table IV
  • figure 2
2012
2012
AbstractBackground: The combination of an inhaled corticosteroid (ICS), budesonide, and a rapid long-acting β2-agonist (LABA… Expand
  • figure 1
  • table I
  • figure 2
  • figure 3
  • table II
Review
2011
Review
2011
C P J / R P C • M A R C H / A P R I L 2 0 1 1 • V O L 1 4 4 , N O 2 Introduction Although chiropractors often practise… Expand
2008
2008
Objective To investigate the efficacy and safety of symbicort turbuhaler in the treatment of mild and moderate patients with… Expand
1990
1990
Terbutaline (Bricanyl®) 0.5 mg t.i.d. administered via Turbuhaler® was compared with fenoterol (Berotec®) 0.2 mg t.i.d… Expand
1989
1989
This study was carried out to investigate if particles approximately less than 5 microns are optimal when delivered from a dry… Expand